$0.69
+0.07 (+10.51%)
Open$0.61
Previous Close$0.62
Day High$0.69
Day Low$0.59
52W High$39.64
52W Low$23.21
Volume—
Avg Volume386.5K
Market Cap4.83M
P/E Ratio—
EPS$-1.85
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+5,126.1% upside
Current
$0.69
$0.69
Target
$36.06
$36.06
$23.45
$36.06 avg
$38.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.10M | 1.13M | 1.14M |
| Net Income | 89.2K | 117.7K | 115.4K |
| Profit Margin | 8.1% | 10.4% | 10.1% |
| EBITDA | 177.4K | 182.1K | 193.3K |
| Free Cash Flow | 70.9K | 72.7K | 77.2K |
| Rev Growth | +5.3% | -7.0% | -3.6% |
| Debt/Equity | 0.17 | 0.19 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |